Primary non-small cell lung cancer response upon treatment with denosumab

A Curioni-Fontecedro; L Husmann; D Soldini; R A Stahel

doi:10.1016/j.lungcan.2013.08.030

Primary non-small cell lung cancer response upon treatment with denosumab

Lung Cancer. 2013 Dec;82(3):506-8. doi: 10.1016/j.lungcan.2013.08.030. Epub 2013 Sep 8.

Authors

A Curioni-Fontecedro¹, L Husmann, D Soldini, R A Stahel

Affiliation

¹ Department of Oncology, University Hospital Zurich, Zurich, Switzerland. Electronic address: [email protected].

PMID: 24075124
DOI: 10.1016/j.lungcan.2013.08.030

Abstract

Here we report the case of a patient with metastatic adenocarcinoma of the lung harboring an ALK gene translocation. In this patient a response of the primary tumor and metastases has been detected upon treatment with denosumab. A possible link between ALK and RANK is postulated.

Keywords: ALK; Crizotinib; Denosumab; NF-kB; Non small cell lung cancer; RANK; RANKL.

Publication types

Case Reports

MeSH terms

Anaplastic Lymphoma Kinase
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / adverse effects
Bronchoscopy
Carcinoma, Non-Small-Cell Lung / diagnosis
Carcinoma, Non-Small-Cell Lung / drug therapy*
Cough
DNA Mutational Analysis
Denosumab
Genes, erbB-1 / genetics
Humans
Lung Neoplasms / diagnosis
Lung Neoplasms / drug therapy*
Male
Middle Aged
Mutation / genetics
Neoplasm Metastasis
Neoplasm Staging
RANK Ligand / immunology
RANK Ligand / metabolism*
Receptor Protein-Tyrosine Kinases / genetics*
Remission Induction
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal, Humanized
RANK Ligand
Denosumab
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases